These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 37028991)
1. Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database. Papp T; Kiss Z; Rokszin G; Fábián I; Márk L; Bagoly Z; Becker D; Merkely B; Aradi D; Dézsi CA; Járai Z; Csanádi Z Clin Ther; 2023 Apr; 45(4):333-346. PubMed ID: 37028991 [TBL] [Abstract][Full Text] [Related]
2. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study. Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163 [TBL] [Abstract][Full Text] [Related]
3. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves. Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436 [TBL] [Abstract][Full Text] [Related]
4. Vitamin K Antagonists and Direct Oral Anticoagulants in Nonagenarian Patients With Atrial Fibrillation. Raposeiras-Roubín S; Alonso Rodríguez D; Camacho Freire SJ; Abu-Assi E; Cobas-Paz R; Rodríguez Pascual C; García Comesaña J; González-Carrero López A; Cubelos Fernández N; López-Masjuán Ríos Á; Cespón-Fernández M; Muñoz-Pousa I; Caneiro-Queija B; Rodríguez Albarrán A; Castañera SÁ; Guillén JV; Carpintero Vara A; Barreiro Pardal C; Domínguez-Erquicia P; Domínguez-Rodríguez LM; Díaz Fernández JF; Fernández Vázquez F; Iñíguez-Romo A J Am Med Dir Assoc; 2020 Mar; 21(3):367-373.e1. PubMed ID: 31753740 [TBL] [Abstract][Full Text] [Related]
5. Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants. Trevisan M; Hjemdahl P; Clase CM; de Jong Y; Evans M; Bellocco R; Fu EL; Carrero JJ Am J Kidney Dis; 2023 Mar; 81(3):307-317.e1. PubMed ID: 36208798 [TBL] [Abstract][Full Text] [Related]
6. Anticoagulation Therapy by Age and Embolic Risk for Nonvalvular Atrial Fibrillation in Mexico, an Upper-Middle-Income Country: The CARMEN-AF Registry. Márquez MF; Baños-González MA; Guevara-Valdivia ME; Vázquez-Acosta J; de Los Ríos Ibarra MO; Aguilar-Linares JA; Jiménez-Cruz M; Matadamas-Hernández N; Camacho-Casillas R; Magaña-Magaña R; Rojel-Martínez U; Alcocer-Gamba MA; Lara-Vaca S; Rodríguez-Reyes H; Islava-Gálvez MA; Betancourt-Hernández LE; Reyes-Reyes N; Beltrán-Gámez ME; Cantú-Brito C; Baños-Velasco AZ; Del Rivero Morfin PJ; González-Hermosillo JA Glob Heart; 2020 Apr; 15(1):32. PubMed ID: 32489805 [TBL] [Abstract][Full Text] [Related]
7. Comparing Vitamin K Antagonists and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement: A Meta-Analysis. Lee WC; Shih JY; Fang HY; Wu PJ; Fang CY; Chen HC; Fang YN; Chang WT; Chen MC Clin Appl Thromb Hemost; 2023; 29():10760296231158585. PubMed ID: 36815218 [TBL] [Abstract][Full Text] [Related]
8. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158 [TBL] [Abstract][Full Text] [Related]
9. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation. Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038 [TBL] [Abstract][Full Text] [Related]
10. Vitamin K antagonists vs. direct oral anticoagulants after transcatheter aortic valve implantation in atrial fibrillation. Butt JH; De Backer O; Olesen JB; Gerds TA; Havers-Borgersen E; Gislason GH; Torp-Pedersen C; Søndergaard L; Køber L; Fosbøl EL Eur Heart J Cardiovasc Pharmacother; 2021 Jan; 7(1):11-19. PubMed ID: 31665260 [TBL] [Abstract][Full Text] [Related]
11. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials. de Lucena LA; Freitas MAA; Souza AKC; Silva CHA; Watanabe JMF; Guedes FL; Almeida JB; de Oliveira RA J Thromb Thrombolysis; 2024 Mar; 57(3):381-389. PubMed ID: 38281231 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922 [TBL] [Abstract][Full Text] [Related]
14. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation. Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Medication Adherence Trajectories to Direct Oral Anticoagulants and Clinical Outcomes in Patients With Atrial Fibrillation. An J; Bider Z; Luong TQ; Cheetham TC; Lang DT; Fischer H; Reynolds K J Am Heart Assoc; 2021 Nov; 10(21):e021601. PubMed ID: 34713708 [TBL] [Abstract][Full Text] [Related]
16. Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience. Spruit JR; de Vries TAC; Hemels MEW; Pisters R; de Groot JR; Jansen RWMM Drugs Aging; 2024 Sep; 41(9):725-740. PubMed ID: 39141209 [TBL] [Abstract][Full Text] [Related]
17. Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and cancer a meta-analysis. Mariani MV; Magnocavallo M; Straito M; Piro A; Severino P; Iannucci G; Chimenti C; Mancone M; Rocca DGD; Forleo GB; Fedele F; Lavalle C J Thromb Thrombolysis; 2021 Feb; 51(2):419-429. PubMed ID: 33044735 [TBL] [Abstract][Full Text] [Related]
18. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
19. Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis. Kattoor AJ; Pothineni NV; Goel A; Syed M; Syed S; Paydak H; Mehta JL J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):428-434. PubMed ID: 31035795 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases. Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]